|1.||Schally, Andrew V: 6 articles (09/2012 - 07/2005)|
|2.||Schally, A V: 6 articles (06/2008 - 01/2000)|
|3.||Siejka, Agnieszka: 4 articles (09/2012 - 05/2010)|
|4.||Barabutis, Nektarios: 4 articles (09/2012 - 05/2010)|
|5.||Varga, J L: 4 articles (05/2001 - 03/2000)|
|6.||Halmos, G: 4 articles (05/2001 - 01/2000)|
|7.||Groot, K: 3 articles (05/2001 - 01/2000)|
|8.||Armatis, P: 3 articles (05/2001 - 01/2000)|
|9.||Hebert, F: 2 articles (07/2000 - 01/2000)|
|10.||Zhang, Qinggui: 1 article (01/2012)|
05/01/2000 - "Exposure in vitro to GH-RH antagonists MZ-5-156 or JV-1 -36 at 1 microM concentration for 24 hours decreased the tumorigenicity of U-87MG cells in nude mice by 10% to 30% and extended the latency period for the development of subcutaneous palpable tumors by 31% to 56%, as compared with the controls. "
05/01/2000 - "After 4 weeks of therapy with MZ-5-156 or JV-1 -36 at the dose of 20 microg/day per animal, the final volume of subcutaneous U-87MG tumors was significantly (P < .01) decreased by 84% and 76%, respectively, as compared with controls. "
07/21/1998 - "After 8 weeks of therapy, final volume and weight of DU-145 tumors in mice treated with MZ-5-156 were significantly (P < 0.01) decreased compared with controls, and serum IGF-I showed a significant reduction. "
07/26/2005 - "Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. "
07/01/2000 - "Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 microgram/day s.c. "
|2.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/01/1996 - "The purpose of this study was to investigate the effects of two potent antagonists of growth hormone-releasing hormone (GH-RH), MZ-4-71 and MZ-5-156 on the growth of the H69 human small cell lung cancer (SCLC) and H157 non-SCLC (NSCLC) lines transplanted into nude mice or cultured in vitro. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
03/01/2008 - "The objective of this study was the investigation of direct anti-proliferative effect of GHRH antagonist MZ-5-156 on HEC-1A human endometrial cancer cell line and the elucidation of underlying mechanisms. "
03/01/2008 - "These results demonstrate that MZ-5-156 can directly inhibit the proliferation of human endometrial cancer cells, which express mRNA for GHRH and SV1 of GHRH receptor, presumably through the induction of p53-dependent apoptosis coupled with the up-regulation of Fas, phospho-p53 (Ser46), p53AIP1, and caspase-8, -9, and -3, and the down-regulation of Bcl-2."
|4.||Carcinoid Tumor (Carcinoid)
09/01/2012 - "In the present study we investigated the in vitro effect of GHRH antagonist, MZ-5-156, on focal adhesion kinase (FAK) activity, on the expression of MMP-2 and MMP-9 metalloproteinases, as well as on vascular endothelial growth factor (VEGF) levels in A549 non-small cell lung (NSCLC) cancer cells and H727 bronchial carcinoid cells. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/05/1999 - "When U-87 glioblastomas, H-69 small cell lung carcinomas, H-23 non-small cell lung carcinomas, and MDA-MB-468 breast carcinoma cells were cultured in vitro, addition of 3 microM MZ-5-156 also inhibited telomerase activity. "
11/01/2011 - "To evaluate the effect of growth hormone-releasing hormone (GHRH) and its antagonist MZ-5-156 on the phosphorylation of AMPK and other related regulatory intracellular proteins we employed human non-small cell lung cancer cell line A549, which expresses GHRH receptors. "
05/01/2010 - "Furthermore, GHRH and its agonist JI-38 upregulates the expression of the proliferative markers cyclin D3 and PCNA in A549 non-small cell lung carcinoma and GHRH antagonist MZ-5-156 downregulates it. "
|1.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|2.||Cyclooxygenase 2 (Cyclooxygenase-2)
|3.||Insulin-Like Growth Factor I (IGF-1)
|4.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
|7.||Focal Adhesion Protein-Tyrosine Kinases
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)